At Astellas, our culture is rooted in openness and integrity, and we continuously work to be a trusted leader in the ever-changing healthcare environment. In step with the evolving global landscape, Astellas will no longer provide funding directly to individual healthcare professionals (HCPs) to attend congresses and conferences, including virtual attendance. This decision is part of our efforts to continue to build our reputation as an ethical company working transparently with our external stakeholders. Our consistent approach to transparency and integrity around the world is critical to our reputation and the trust we share with healthcare professionals, the patients they serve, and the broader healthcare community.

Here in Greek market and around the world, Astellas remains committed to providing ongoing high-quality medical education opportunities that help ensure appropriate clinical use of our existing medications and new medical innovations, fulfil educational needs/gaps and, ultimately, improve patient care. Astellas will continue to share new scientific data and disease information in a variety of formats that support the critical role of HCPs in improving patient care, including:

  • Grants to HCOs for Medical Education
  • Symposia, webinars, e-learnings and web-based education (disease, treatment or product focused);
  • Congress summaries
  • Sponsorship of educational conferences

Astellas is exploring opportunities to increase digital/virtual options for medical education. We continuously seek to identify and understand the educational gaps within disease states of interest to Astellas in order to create and tailor meaningful educational programs that fulfil healthcare providers’ information needs.

We will continue to assess how we can evolve and enhance our medical education offerings to meet the ever-changing needs of the healthcare community and ensure healthcare professionals will continue to have access to the latest available data to understand clinical use of our existing medications and new medical innovations.

NON_2020_0062_GR